IAG Wealth Partners’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-3,000
Closed -$483 541
2024
Q4
$483 Hold
3,000
﹤0.01% 492
2024
Q3
$694 Hold
3,000
﹤0.01% 471
2024
Q2
$1.63K Hold
3,000
﹤0.01% 458
2024
Q1
$3.06K Hold
3,000
﹤0.01% 394
2023
Q4
$1.71K Hold
3,000
﹤0.01% 389
2023
Q3
$3.12K Hold
3,000
﹤0.01% 378
2023
Q2
$4.23K Buy
+3,000
New +$4.29K ﹤0.01% 379

Other funds holding VIRX

IAG Wealth Partners's VIRX Position: Q1 2025 in Review

IAG Wealth Partners sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 3,000 shares — an estimated $483 sold.

IAG Wealth Partners first reported a position in VIRX in Q2 2023 and held it in 7 quarters. The position peaked at $4.23K in Q2 2023. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • IAG Wealth Partners reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • IAG Wealth Partners sold 3,000 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $483.
  • IAG Wealth Partners first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2023 and held it in 7 quarters.
  • IAG Wealth Partners's Viracta Therapeutics, Inc. Common Stock position peaked at $4.23K in Q2 2023.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on IAG Wealth Partners's 13F filing for Q1 2025, filed 16 Apr 2025.